Associations of methadone and buprenorphine-naloxone doses with unregulated opioid use, treatment retention, and adverse events in prescription-type opioid use disorders: Exploratory analyses of the OPTIMA study
PsiquiatriaSobre o estudo
- Desenho
- Ensaio clínico randomizado
- Nível de evidência
- 2 · Nova evidência
- Revista
- The American journal on addictions
- Publicado em
- 12 jun 2023
- Citações
- 15
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Associations of methadone and buprenorphine-naloxone doses with unregulated opioid use, treatment retention, and adverse events in prescription-type opioid use disorders: Exploratory analyses of the OPTIMA study
Hamzah Bakouni, Christina McAnulty, Ovidiu Tatar, M Eugenia Socias, Bernard Le Foll, Ron Lim, Keith Ahamad, Didier Jutras-Aswad, OPTIMA Research Group within the Canadian Research Initiative in Substance Misuse
Descritores MeSH
- Buprenorphine
- Opioid-Related Disorders
- Canada
- Heroin
- Humans
- Methadone
- Narcotic Antagonists
- Prescriptions
- Buprenorphine, Naloxone Drug Combination
- Opiate Substitution Treatment
Veja também
Estudos relacionados
- Effects of Buprenorphine/Naloxone and Methadone on Depressive Symptoms in People with Prescription Opioid Use Disorder: A Pragmatic Randomised Controlled Trial
- Flexible Buprenorphine/Naloxone Model of Care for Reducing Opioid Use in Individuals With Prescription-Type Opioid Use Disorder: An Open-Label, Pragmatic, Noninferiority Randomized Controlled Trial
- Opioid agonist treatment outcomes among individuals with a history of nonfatal overdose: Findings from a pragmatic, pan-Canadian, randomized control trial
- Mediating effect of craving on the impact of buprenorphine/naloxone and methadone treatment on opioid use: Results from a randomized controlled trial